Clinical Trial to Assess Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-Сov-2) Infection

Phase 2

• Conditions: COVID-19 Prevention
• Interventions: Biological: Gam-COVID-Vac; Other: Placebo

• Registration Number: NCT04640233
• Lead Sponsor: Dr. Reddy's Laboratories Limited

Brief Summary

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.

Detailed Description

Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multi-Centre Phase II/III Adaptive Clinical Trial to Assess the Safety and Immunogenicity of Gam-COVID-Vac Combined Vector Vaccine for SARS-Сov-2 Infection in Indian Healthy Subjects.

In phase II trial, 100 subjects of immunogenicity group will be enrolled in 3:1 (Test:Placebo) ratio. These 100 subjects will be assessed for safety and immunogenicity outcomes till Day 28 post the first dose of investigational medicinal product (IMP)/placebo administration and will continue with study assessments till Day 180. Safety and immunogenicity data collected till Day 28 will be submitted to the regulatory authority for recommendation to proceed with Phase III recruitment.

In Phase III trial, 1500 subjects will be enrolled and randomized in the ratio of 3:1 (Gam-COVID--Vac : Placebo).

Each subject will participate in this adaptive study phase II/III clinical trial for 180±14 days after the first dose of the IMP/placebo and will have one screening visit and seven on-site visits during the trial period. The IMP/placebo will be administered intramuscularly during vaccination Visits 1 and 3 (Day 1 and Day 21±2). The observation Visits 2, 4, 5, 6, and 7 will be made on Day 19±2, Day 28±2, Day 42±2, Day 90±7, and Day 180±14, respectively. During the observation visits, vital indicators will be assessed in all subjects and changes in the subjects' condition and well being compared to the previous visit will be recorded. The schedule of examination procedures is mentioned in the Schedule of Event tables.

Additionally, the subjects will be able to have remote consultations with the study physician through the weekly telephonic follow-up.

Blood samples will be taken from immunogenicity group of phase II (all 100) and phase III (284 out of 1500) trials during the following visits to assess the immunogenicity parameters.

Study Timeline

• Study First Submitted: 2020-11-17
• Study First Submitted QC: 2020-11-20
• Study First Posted: 2020-11-23
• Study Start: 2020-11-30
• Status Verified: 2021-05
• Last Update Submitted: 2021-05-31
• Last Update Posted: 2021-06-02
• Primary Completion: 2021-08
• Study Completion: 2021-09

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 1600

Inclusion Criteria

1. Written informed consent of a subject to participate in the trial
2. Males and females aged 18+ years
3. Negative human immunodeficiency virus (HIV 1 & 2) and hepatitis B and C test results
4. Negative immunoglobulin M (IgM) and immunoglobulin G (IgG) SARS-CoV-2 antibodies through enzyme immunoassay test result
5. Negative COVID-2019 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) test result at the screening visit (72 hours prior to Visit 1 [Day 1])
6. No COVID-2019 in the medical history
7. History of no contact with COVID-2019 persons within at least 14 days before the enrolment (according to subjects)
8. Consent for using effective methods of contraception during the entire trial 1
9. Negative urine pregnancy test at the screening visit (for child-bearing age women)
10. No evident vaccine-induced reactions or complications after receiving immunobiological products in the medical history
11. No acute infectious and/or respiratory diseases within at least 14 days before the enrolment.

Exclusion Criteria

1. Any vaccination/immunization within 30 days before the enrolment
2. Steroids (except hormonal contraceptives) and immunoglobulins or other blood products therapy not finished 30 days before the enrolment
3. Immunosuppressors therapy finished within 3 months before the enrolment
4. Pregnancy or breast-feeding
5. Acute coronary syndrome or stroke suffered less than one year before the enrolment
6. Tuberculosis, chronic systemic infections
7. Drug allergy (anaphylactic shock, Quincke edema, polymorphic exudative eczema, atopy, serum disease),hypersensitivity or allergic reaction to immunobiological products, known allergic reactions to study product components, acute exacerbation of allergic diseases on the enrolment day
8. Subjects who are on drugs that could have potential drug interactions with adenovirus vaccine
9. Medical history of malignancy
10. Donated blood or plasma (450+ mL) within 2 months before the enrolment
11. Splenectomy in the medical history
12. Neutropenia (absolute neutrophil count less than 1,000 mm3), agranulocytosis, significant blood loss,severe anaemia (haemoglobin less than 80 g/L), immunodeficiency including autoimmune disorders in the medical history within 6 months before the enrolment
13. Active form of a disease caused by the HIV and hepatitis B or C
14. Anorexia, protein deficiency of any origin
15. Tattoos at the injection site (deltoid muscle area), which does not allow assessing the local response to the IMP or placebo administration
16. Alcohol or drug addiction in the medical history.
17. Participation in any other interventional clinical trial within 1 month prior to the Screening
18. Any other medical condition that would limit the participation of the subject as per Investigator discretion
19. Study centre staff or other employees directly involved in the trial and their families
20. Subjects contraindicated for vaccination

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Primary Group	Gam-COVID-Vac	Gam-COVID-Vac combined vector vaccine, 0.5 ml/dose + 0.5 ml/dose prime-boost immunization on day 1 (component I rAd26-S) and on day 21 (component II rAd5-S)
Control Group	Placebo	Placebo, 0.5 ml/dose + 0.5 ml/dose immunization on days 1 and 21

Primary Outcome Measures

Name	Time	Method
Immunogenicity	For Phase III study - Day 42 after first dose	For Phase III study - Geometric mean titre ratio of SARS-CoV-2 glycoprotein-specific antibodies between IMP and placebo in immunogenicity group
Adverse Events	For Phase II study - at Day 28; For Phase III study - till day 180 after first dose	For Phase II study - - Incidence \& severity of adverse events (AEs) after first dose of IMP/Placebo; For Phase III study -; - Incidence of related serious adverse events (SAEs) following vaccination during the study

Secondary Outcome Measures

Name	Time	Method
Adverse Events	Baseline to Day 180	Incidence and severity of adverse events after injecting the first dose of the IMP/placebo; Incidence of SAE following vaccination
Immunogenicity assessment	Baseline, Day 28, Day 42, Day 90 and Day 180	The number of proliferating cluster of differentiation 4 (CD4) cell and cluster of differentiation 8 (CD8) cells in response to mitogen stimulation in cell mediated immunogenicity group
Percentage of subjects with mild, moderate, severe coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose of the vaccine/placebo	Baseline to Day 180	Comparing percentage of subjects developing COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo based on severity course
Incidence of coronavirus disease 2019 (COVID-19) developed within 6 months after the first dose in trial subjects	Baseline to Day 180	Comparing incidence of COVID-19 disease between Gam-COVID-Vac combined vector vaccine and placebo

Trial Locations

Locations (23)

HIMSR with CHRD-SAS; 🇮🇳 Delhi, India

GSVM Medical College; 🇮🇳 Kanpur, India

KEM Hospital; 🇮🇳 Pune, India

ESIC Medical College & Hospital; 🇮🇳 Faridabad, India

Peerless Hospital; 🇮🇳 Kolkata, India

Rhythm Heart Institute; 🇮🇳 Vadodara, India

Batra Hospital; 🇮🇳 Delhi, India

AIG hospital; 🇮🇳 Hyderabad, India

Maharaja Agrasen Superspecialty Hospital; 🇮🇳 Jaipur, India

JSS Hospital; 🇮🇳 Mysore, India

Noble Hospital Private Limited; 🇮🇳 Pune, India

BAPS hospital; 🇮🇳 Sūrat, India

S N Medical College; 🇮🇳 Agra, India

MGM Medical College and Hospital; 🇮🇳 Aurangabad, India

KLE Prabhakar Kore Hospital; 🇮🇳 Belgaum, India

Apollo Hospital; 🇮🇳 Delhi, India

Atharva Hospital; 🇮🇳 Lucknow, India

St. George's Hospital; 🇮🇳 Mumbai, India

INCLEN trust and Gurunanak Hospital; 🇮🇳 Palwal, India

PIMS; 🇮🇳 Puducherry, India

BJ Sassoon Hospital; 🇮🇳 Pune, India

Sumandeep Vidyapeeth; 🇮🇳 Vadodara, India

Christian Medical College; 🇮🇳 Vellore, India